Based on the Phathom Pharmaceuticals Inc stock forecast from 3 analysts, the average analyst target price for Phathom Pharmaceuticals Inc is USD 22.64 over the next 12 months. Phathom Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Phathom Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Phathom Pharmaceuticals Inc’s stock price was USD 10.04. Phathom Pharmaceuticals Inc’s stock price has changed by +9.37% over the past week, +1.83% over the past month and -13.60% over the last year.
No recent analyst target price found for Phathom Pharmaceuticals Inc
No recent average analyst rating found for Phathom Pharmaceuticals Inc
Company Overview Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Read Less
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that...Read More
Frequently Asked Questions About Phathom Pharmaceuticals Inc (PHAT) Stock
Based on ratings from 3 analysts Phathom Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on PHAT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for PHAT is USD 22.64 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 10.
PHAT stock's Price/Earning ratio is -99,999.99.
Our analysis grades PHAT stock's Price / Earning ratio at A+. This means that PHAT stock's Price/Earning ratio is above 2.000000000000002% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PHAT may be undervalued for its sector.
The last closing price of PHAT's stock was USD 10.04.
The most recent market capitalization for PHAT is USD 0.62B.
Based on targets from 3 analysts, the average taret price for PHAT is projected at USD 22.64 over the next 12 months.
This means that PHAT's stock price may go up by +125.46% over the next 12 months.
Following are ETFs with the highest allocation to Phathom Pharmaceuticals Inc's stock :
As per our most recent records Phathom Pharmaceuticals Inc has 452 Employees.
Phathom Pharmaceuticals Inc's registered address is 100 Campus Drive, Florham Park, NJ, United States, 07932.
You can get more information about it from Phathom Pharmaceuticals Inc's website at https://www.phathompharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PHAT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
